Research Associate/Senior Research Associate, Stem Cell Biology

Company Summary:

Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Position Summary:

We are looking for a Research Associate to join the In Vivo Rewriting Candidate Development team to advance translational research with Tessera’s novel Gene Writing and Gene Rewriting technology for in vivo gene therapy applications. The Research Associate will work closely with scientists to translate novel gene writing technologies to develop innovative therapeutics. We are searching for a driven, enthusiastic, and self-motivated individual who is comfortable multi-tasking and working independently on various aspects of the platform. This individual will join a dynamic, rapidly growing, and highly collaborative team.

Key Responsibilities:

• Maintain human iPSC clones and differentiate human iPSC to hepatocytes according to established protocols
• Provide laboratory support to maintain available stocks of critical cell culture reagents
• Independently contributes to scientific experiments, such as flow cytometry, ELISAs, PCR, or other molecular biology and immunology techniques
• Coordinate with other scientists and research associates to deliver cell samples for downstream applications within defined timelines.

Basic Qualifications:

• BS/MS degree in biological sciences with 1+ years of laboratory experience
• Extensive experience with mammalian cell culture is required
• Previous experience with flow cytometry, western blot, and/or PCR-based assays
• Highly organized with significant attention to detail
• Flexibility and adaptability to changing priorities in a fast-paced, dynamic team environment

Preferred Qualifications:

• Experience with human iPSC culture and in-vitro differentiation
• Experience in non-viral or viral gene delivery methods, including electroporation, nucleofection and viral transduction
• Experience in developing and executing assays to characterize hepatocyte function

More About Flagship Pioneering

Flagship Pioneering has conceived of and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Editas Medicine (NASDAQ: EDIT), Omega Therapeutics (NASDAQ: OMGA), Seres Therapeutics (NASDAQ: MCRB), and Indigo Agriculture. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures. In 2021, Flagship Pioneering was ranked 12th globally on Fortune’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

 

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.